Betadermic

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Betadermic

Quick Facts

Property Description
Active Ingredients Betamethasone Dipropionate, Sodium Salicylate
Form Topical Solution (Cutaneous Solution)
Pharmacological Class Potent Topical Corticosteroid + Salicylate Derivative
Common Use Context Management of Inflammatory Skin Conditions
Origin Synthetic Combination Drug

What Is the Pharmaceutical Identity and Type of Betadermic?

Betadermic is defined as a prescription-only combination drug specifically designed as a topical dermatological agent for application directly to the skin. It is manufactured as a Topical Solution, a liquid formulation that facilitates effective and localized delivery of the active components, particularly on areas with hair. This medicine is entirely a synthetic preparation, meaning its active components are produced through chemical synthesis rather than being naturally derived compounds. Betadermic is clinically recognized for its use in conditions where inflammation is coupled with hyperkeratosis or scaling, distinguishing it from simple corticosteroid creams or ointments.

Composition and Pharmacological Class of Betadermic

The core identity of Betadermic rests on its dual active ingredients: Betamethasone Dipropionate and Sodium Salicylate. This mixture establishes its comprehensive pharmacological class as a Potent Topical Corticosteroid combined with a Salicylate derivative.

Betamethasone Dipropionate functions as the high-potency glucocorticoid, primarily responsible for the significant anti-inflammatory and localized immune-suppressing actions. The second component, Sodium Salicylate, is included for its secondary, surface-level effect: it acts as a keratolytic agent, helping to soften and loosen the thickened or scaly outer layers of the skin. Combining these agents allows the salicylate component to enhance the corticosteroid's ability to penetrate the skin barrier and reach the affected tissue. This synergistic composition addresses the need for both potent immune modulation and surface preparation.

Betadermic's General Purpose: Dual Action for Inflammatory Skin

The general purpose of Betadermic is to provide intense relief and normalization for inflammatory skin conditions characterized by severe scaling and irritation, utilizing its specialized dual action. The potent anti-inflammatory properties quickly work to alleviate symptoms like swelling, redness, and pruritus (itching). Concurrently, the keratolytic action ensures that the medicine is able to penetrate the often-thickened skin barrier, optimizing the therapeutic effect of the corticosteroid on the underlying inflammation. A typical use scenario involves managing thick, flaky patches that have not responded adequately to lower-potency treatments, relying on the high-potency and synergistic formulation of Betadermic to improve skin texture and reduce discomfort.

Regulatory References

  1. Betamethasone Dipropionate (Augmented) - DailyMed
  2. Salicylic Acid Topical - DailyMed
  3. Topical Corticosteroid Potency Classification - NIH/StatPearls
  4. Salicylates - National Library of Medicine
  5. Dermatitis - NIH MedlinePlus
  6. DIPROSALIC Product Information - Health Canada
  7. Dermatologic Agents - National Library of Medicine (MeSH)
  8. Synthetic Drugs - National Library of Medicine (MeSH)
  9. Betamethasone/Salicylic Acid Product Information - Health Canada
  10. NIH/PMC4374065 - Synergistic Action

What side effects are possible with Betadermic?

Possible Side Effects and Safety Information

The safety profile for Betadermic, a potent topical corticosteroid combined with a salicylate derivative, is officially categorized by adverse reactions primarily affecting the skin, alongside potential systemic effects stemming from the absorption of the corticosteroid component. The overall regulatory safety documentation distinguishes between local reactions, which are generally more frequent, and rare but serious systemic consequences.

Local and Dermatological Adverse Reactions

Adverse reactions at the application site are frequently documented. These common effects include burning sensation, itching (pruritus), and irritation. Less common reactions listed in regulatory sources include folliculitis, hypertrichosis (excessive hair growth), and changes to the skin's texture such as skin atrophy (thinning) and striae (stretch marks), which are associated with more prolonged use.

Systemic Safety Concerns

The most serious safety concerns are linked to systemic absorption, primarily categorized as Endocrine Disorders. Official documents list the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome as rare but clinically significant consequences. Systemic effects can also include ophthalmologic disorders, such as the potential for glaucoma or cataracts with extended use.

Population-Specific and Exposure Notes

Regulatory safety statements highlight specific vulnerability in pediatric patients, who have a greater risk for systemic toxicity, including documented effects such as linear growth retardation. The risk of serious adverse reactions is consistently noted to increase under conditions that enhance absorption, such as application over large surface areas, prolonged continuous use, or the use of occlusive dressings.

Overdose and Emergency Response

Overdose and When to Seek Help

Systemic toxicity from Betadermic is officially documented to occur due to the excessive, prolonged use or application over large surface areas, which results in significant systemic absorption of both active components.

Component Documented Overdose Syndrome
Betamethasone Dipropionate Hypercorticism and HPA Axis Suppression
Sodium Salicylate Salicylism

Documented Manifestations

Overdose may present with signs related to either component. Hypercorticism can manifest as Cushing's syndrome or secondary adrenal insufficiency, with documented risks including hyperglycemia and glucosuria. Salicylism symptoms include severe confusion, vomiting, dizziness, tinnitus, and hyperventilation, potentially leading to respiratory alkalosis. Severe outcomes, such as seizures, cerebral edema, and cardiac dysrhythmias, are associated with salicylate toxicity.

Mandated Emergency Action

The appearance of any signs or symptoms of systemic toxicity requires that immediate medical attention must be sought. This is due to the potential for life-threatening outcomes, such as adrenal crisis or severe salicylate poisoning.

Overdose Management and Considerations

No specific pharmacological antidote is described for either component. Management procedures officially focus on symptomatic treatment, gradual withdrawal of the steroid, and enhancing the elimination of the salicylate (e.g., through procedures like urine alkalinization). The pediatric population is specifically identified as being at greater risk of systemic toxicity, including linear growth retardation, due to a higher skin surface area-to-body mass ratio.

Therapeutic Uses of Betadermic

Main Uses and Benefits of Betadermic

Betadermic is a combination topical medication designed to treat inflammatory skin conditions where a secondary bacterial infection is either present or likely to occur. By combining a corticosteroid with an antibiotic, the medication addresses both the underlying skin inflammation and the complicating bacterial presence.

Therapeutic Indications

This medication is primarily used for the management of several localized skin disorders, including:

  • Eczema and Dermatitis: This includes atopic dermatitis, contact dermatitis, and seborrheic dermatitis. It is effective in reducing the redness, swelling, and itching associated with these flare-ups.
  • Psoriasis: It is used to manage localized plaques of psoriasis, helping to reduce skin thickening and scaling.
  • Lichen Planus: The treatment helps alleviate the discomfort and appearance of this inflammatory skin condition.
  • Insect Bite Reactions: It can be applied to severe local reactions to insect bites that show signs of secondary infection.

Primary Benefits

  • Reduction of Inflammation: The corticosteroid component works to constrict blood vessels and suppress the immune response in the skin, leading to a rapid reduction in swelling and redness.
  • Symptom Relief: It provides relief from persistent itching (pruritus) and burning sensations, which helps prevent further skin damage caused by scratching.
  • Antibacterial Action: The inclusion of an antibiotic helps eliminate susceptible bacteria, preventing a minor skin irritation from developing into a more serious infection.
  • Dual-Action Support: By treating the infection and the inflammation simultaneously, the medication supports a more efficient healing environment for the skin barrier.

Eligibility and Restrictions for Use

Who Can and Cannot Use Betadermic? (Betamethasone Valerate)

Eligibility for Betadermic is strictly determined by regulatory contraindications and restrictions related to age, physiological status, and existing conditions. This information is based on official government regulatory documents.

Absolute Contraindications (Must Not Use)

Category Exclusion Criteria
Allergy Known hypersensitivity to betamethasone valerate or any other ingredient.
Skin Conditions Untreated cutaneous infections (viral, fungal, bacterial), rosacea, acne vulgaris, perioral dermatitis, or pruritus without inflammation.
Age Infants under one year of age (for dermatoses).

Populations Requiring Restricted or Conditional Use

  • Pediatric Patients: Use in children is restricted due to a higher risk of systemic toxicity (HPA axis suppression). Chronic or large-area therapy must be avoided. Safety and efficacy for certain formulations may not be established.
  • Pregnancy and Lactation: Use is conditional; it should only occur if the potential benefit justifies the potential risk to the fetus or infant. Application to the breast during nursing is not recommended.
  • Systemic Risk: Patients with conditions like diabetes, Cushing's syndrome, or liver failure should use Betadermic with caution, as systemic absorption may worsen these conditions.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The officially documented interaction profile for Betadermic is defined by the systemic absorption of its two active components, Betamethasone Dipropionate and Sodium Salicylate, from the skin surface. Interactions arise when the absorbed ingredients reach levels capable of influencing the effect of other systemically administered medicines, requiring caution or monitoring.

Pharmacodynamic Interactions

The corticosteroid component may oppose the action of antidiabetic agents (such as insulin) by potentially raising blood glucose levels, a formally documented pharmacodynamic interaction. Concurrently, the salicylate component, when absorbed systemically, may potentiate the effects of oral anticoagulants (such as Warfarin), creating an increased risk of bleeding complications. Co-administration with other corticosteroid-containing products (topical or systemic) increases the overall corticosteroid load, compounding the risk of systemic interactions.

Exposure-Related Constraints and Patient Risk

The use of occlusive dressings (including bandages or tight clothing) is documented as an application-related restriction because it significantly increases systemic absorption, thereby magnifying the potential for all systemic interactions. Furthermore, regulatory documents cite pediatric patients and individuals with liver failure as populations with an increased susceptibility to systemic adverse reactions due to a greater surface area-to-mass ratio or potential reduction in metabolic clearance, respectively.

Mechanism of Action

Targeted Modulation of Genetic Activity

Betadermic acts as an agonist for the intracellular Glucocorticoid Receptor (GR), initiating a cascade that involves the binding and transport of the drug-receptor complex into the cell nucleus. This action directly engages the genetic machinery, leading to the upregulation of genes that produce anti-inflammatory proteins while simultaneously repressing genes responsible for pro-inflammatory signaling.


Regulating Inflammatory Pathways

The drug's mechanism is involved in inhibiting inflammatory pathways, specifically by interfering with transcription factors like NF-kappa B. By blocking these factors, Betadermic limits the synthesis of a broad range of pro-inflammatory mediators (cytokines and chemokines), which alters the signaling intensity within the tissue response.


Limiting Local Vascular and Cellular Response

The molecular cascades ultimately result in tangible physiological adjustments at the site of action, notably vasoconstriction (narrowing of local blood vessels) and a reduction in capillary permeability. These effects contribute to limiting the migration of immune cells into the tissue and reducing fluid accumulation, which results in the modulation of the physiological response.

Dosage and Administration Information

Betadermic, a topical ointment containing the high-potency corticosteroid Betamethasone Dipropionate and Salicylic Acid, is intended for external application only, as directed by a healthcare provider. It is used to relieve the inflammatory and pruritic manifestations of certain corticosteroid-responsive dermatoses, such as psoriasis.

Application Instructions

Guideline Detail
Preparation Wash hands before and after application. Cleanse and dry the affected skin area.
Dosing Apply a thin film of the ointment to the affected skin areas once or twice daily, as prescribed. Gently rub the product into the skin.
Duration Therapy should be discontinued when control of the condition is achieved. Treatment with high-potency corticosteroids like Betamethasone Dipropionate should not exceed the duration prescribed by a physician, often limited to a few weeks, to minimize the risk of adverse effects, including Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.
Maximum Use Do not use more than 50 grams per week unless specifically instructed by a physician.

Important Precautions

Avoid using the ointment on the face, groin, or axillae (underarms), or on areas where skin atrophy (thinning) is already present. Do not use occlusive dressings (airtight coverings, such as bandages or plastic wrap) over the treated area unless specifically directed by your physician, as this can increase systemic absorption of the corticosteroid. The medication is strictly for topical (skin) use; it must not be used in the eyes, mouth, or vagina. If irritation or signs of a secondary infection develop, discontinue use and consult a healthcare professional.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Betadermic

This section summarizes the published research on the Betadermic combination (betamethasone dipropionate and salicylic acid), detailing what has been studied, how findings were measured, and where evidence gaps exist. This information provides context but does not constitute medical advice or a prediction of individual outcomes.


Evidence for Use in Chronic Plaque Psoriasis

The research on Betadermic in chronic plaque psoriasis, a condition characterized by fluctuating or episodic manifestations and periods of heightened symptom activity, was used in studies examining short-term symptom patterns.

The evidence primarily comes from formal studies known as Randomized Controlled Trials (RCTs) and systematic reviews. Researchers examined measurements of disease severity, such as the Psoriasis Area and Severity Index (PASI), and symptom-specific outcomes monitored in trials, including scaling (hyperkeratosis), redness, and pruritus (itching). Studies observed patterns related to different locations, including scalp psoriasis.

Findings describe patterns observed in the studies, mostly over short-term periods (typically 2 to 4 weeks). Some trials described patterns where a higher proportion of individuals met the criteria for “clear” or “almost clear” status, as defined by the study, when compared to monotherapy or a vehicle control. This research contributes to the broader evidence landscape, and its consistency was categorized as High in the context of short-term symptom monitoring.


Evidence for Use in Eczema and Scaling Dermatoses

The Landscape of Long-Term Studies and Follow-Up

For the Betadermic combination, the definitive comparative studies observed responses over limited, defined time intervals, primarily lasting 2 to 12 weeks. Follow-up durations were limited across the core research base. Given the focus on short-term research, there is limited information for long-term outcomes regarding this specific combination. Consequently, the durability of any measured response is not fully established. Research provides limited insight into long-term maintenance strategies or how the skin condition evolves after the observed treatment period concludes.


Evidence in Different Patient Groups

Studies monitored patterns observed in specific populations where the combination was studied. The research describes patterns observed in study populations, primarily adult out-patients diagnosed with mild-to-moderate conditions.

Definitive comparative evidence for use in children and adolescents is still emerging, meaning the research is not broadly available to describe outcomes in these younger populations. Studies were primarily conducted in out-patients without severe systemic comorbidities. Therefore, research provides limited context regarding outcomes in individuals with complex accompanying health issues.


What is Still Uncertain in the Research Record

While a high volume of short-term data exists for psoriasis, the certainty remains low when examining long-term outcomes. Furthermore, comparative evidence is limited against some common, non-steroid topical treatments. It is crucial to remember that research provides context but not individual predictions; findings describe group patterns, not personal outcomes.

Key Studies & References Rationales for combination treatment in psoriasis: a systematic review and clinical implications

Frequently Asked Questions (FAQ)

Common questions about Betadermic (FAQ)


Q: How quickly does Betadermic start working for skin inflammation?

A: Studies and official product information indicate that for inflammatory skin conditions, improvement in symptoms such as itching, redness, and scaling is often noted within the first week of application. This timeframe is consistent with the known action of high-potency topical corticosteroids.


Q: Is Betadermic considered a strong corticosteroid cream?

A: Yes, Betadermic contains Betamethasone Dipropionate, which is classified in official regulatory documents as a high-potency or super-high potency topical corticosteroid. This classification reflects its powerful anti-inflammatory effect.


Q: How long can I safely use Betadermic cream for?

A: Official guidelines emphasize that high-potency topical corticosteroids should be used for the shortest possible duration to reduce risk, often no more than two consecutive weeks for adults. Duration of use is a decision that must be made in consultation with a healthcare professional.


Q: What are the most common side effects of using Betadermic?

A: The most frequently reported local adverse reactions, according to official labeling, include temporary sensations at the application site. These often involve a burning sensation, stinging, irritation, or itching.


Q: Does Betadermic thin the skin if used for a long time?

A: Yes, prolonged and continuous use of the corticosteroid component is associated with local changes. Regulatory documents list the potential for adverse effects like skin atrophy (thinning) and striae (stretch marks).


Q: Is Betadermic safe to use during pregnancy?

A: Official labeling for Betadermic states that its use during pregnancy is conditional. It should only be used if the potential benefit justifies the potential risk to the developing fetus. Any decision regarding use during pregnancy requires assessment by a healthcare professional.


Q: What happens if I accidentally swallow a small amount of Betadermic?

A: Betadermic is strictly for external skin use, and ingestion is harmful. Accidental swallowing may lead to symptoms related to either the salicylate or corticosteroid components. Immediate medical attention may be required.


Q: Are there long-term side effects associated with Betadermic use?

A: Yes, long-term use is associated with a greater risk of adverse reactions. These include local effects like skin atrophy and more serious systemic effects like HPA axis suppression (a condition involving the hormonal system) or ophthalmologic issues like glaucoma.


Q: Does Betadermic help with itching or just redness?

A: Official information indicates that Betadermic is used for the relief of both inflammatory manifestations (which includes redness) and pruritic manifestations, meaning it is intended to help with itching as well.


Q: Is there a generic version of Betadermic?

A: The product is a combination of two active ingredients, Betamethasone Dipropionate and Salicylic Acid. As a combination of active ingredients, information regarding generic availability can be found in official drug databases.


Q: Does the strength of Betadermic vary by percentage?

A: Yes, different formulations, such as the ointment or solution, can contain the active ingredients at varying concentration levels. The specific strength of the product used is determined by the prescribing healthcare professional.


Q: Can I use Betadermic if I have a skin infection?

A: Official contraindications state that Betadermic should not be used in individuals with untreated cutaneous infections, which includes fungal, viral, or bacterial infections. This medicine has the potential to mask certain infections.


Q: What's the difference between the cream and the ointment form of Betadermic?

A: The primary differences lie in the inactive ingredients (vehicle) that carry the medicine. For example, the ointment typically contains petrolatum and is more occlusive (seals in moisture), while the solution is liquid and commonly used for the scalp or other hair-bearing areas.


Q: Can sun exposure affect the use of Betadermic?

A: The Salicylic Acid component in Betadermic can potentially increase the skin's sensitivity to UV light in some users. Due to this potential, appropriate precautions against sun exposure may be discussed with a healthcare professional.


Q: Is Betadermic available over the counter?

A: No. Official labeling indicates that Betadermic is a prescription-only medicine (Rx only) and requires a prescription from a licensed healthcare provider for dispensing.


Q: Can Betadermic be used on the face?

A: No. Official labeling and warnings explicitly advise against using Betadermic on the face, groin, or underarms (axillae). This is because the skin in these areas is thinner and more susceptible to side effects like skin atrophy.


Q: Is it normal for Betadermic to cause a slight stinging sensation initially?

A: Yes, a slight stinging is considered normal. Regulatory documents list stinging, along with burning sensation and irritation, as common local adverse reactions that may occur, particularly when treatment is first started.


Q: Are there any known drug interactions with Betadermic?

A: Yes. Interactions are possible due to the absorption of the active ingredients through the skin. Official labeling warns about potential interaction with antidiabetic agents (which could raise blood sugar) and oral anticoagulants (which could increase bleeding risk).


Q: Does alcohol interact with Betadermic when applied topically?

A: Regulatory documents for the solution formulation may note that it contains alcohol, classifying it as a serious fire hazard. It is advised that individuals avoid smoking or naked flames during or shortly after application of the solution.


Q: What should I do if I forget to apply a dose of Betadermic?

A: Regulatory documents include specific directions on how to handle a forgotten dose, which typically involves applying it as soon as possible unless the next dose is due. This is generally detailed in the patient information leaflet.


Q: Is Betadermic effective for treating severe eczema patches?

A: The core clinical trials for this product focused mainly on patients with mild-to-moderate conditions, and the research does not fully describe outcomes for individuals with very severe systemic conditions. Any decision regarding its use for severe patches is a determination made by the prescribing healthcare professional.


Q: Can Betadermic affect blood sugar levels?

A: Yes. Systemic absorption of the corticosteroid component has the potential to cause hyperglycemia (raised blood glucose levels). This is why the product labeling warns that it may oppose the action of antidiabetic medicines.


Q: Can I use Betadermic with other topical medicines?

A: Any concurrent use of Betadermic with other topical medicines requires consultation with a healthcare professional. Co-administering it with other corticosteroid-containing products (topical or systemic) is specifically warned against as it compounds the risk of systemic exposure.


Q: What are the signs of absorbing too much Betadermic through the skin?

A: Signs of absorbing too much medication, which can lead to HPA axis suppression (a condition involving the hormonal system), may include symptoms like severe fatigue, weakness, mood changes, or, in rare cases, physical signs of Cushing's syndrome.


Q: Does Betadermic contain petrolatum?

A: Yes, official documents detailing the inactive ingredients state that the ointment formulation typically contains white petrolatum and mineral oil, which contribute to its thick, occlusive base.


Q: Can using Betadermic mask a fungal infection?

A: Yes, corticosteroids have immune-suppressing effects that can potentially mask the presence or worsen an existing skin infection. For this reason, it is contraindicated for use with untreated infections.


Q: Can older adults use Betadermic safely?

A: Official product information suggests that the product is generally considered safe for use in the geriatric population. However, caution is advised as older adults may have age-related conditions, such as naturally thinner skin, that increase the risk of side effects.


Q: Is it normal to see some mild discoloration where Betadermic is applied?

A: Less common adverse reactions reported with topical corticosteroids include hypopigmentation, which is a lightening or discoloration of the skin where the product is applied. Skin discoloration is a reaction that may be discussed with a healthcare professional.


Q: What is the expiration date on Betadermic based on?

A: Official stability information specifies two dates: the labeled expiry date of the unopened product, and a specific use-by-date once the package is opened. For example, some solutions must be used within 6 weeks after first opening the bottle.

How should Betadermic be stored and disposed of?

The storage and disposal of Betadermic Topical Solution must strictly follow official regulatory guidelines to maintain its effectiveness and ensure safety.

Item Official Storage Requirement
Temperature Do not store above 25 C; keep from freezing.
Stability Use within 6 weeks after first opening the bottle; do not use past the labeled expiry date.
Container Keep the medicine in its original container, tightly closed.
Protection Keep this medicine out of the sight and reach of children.
Handling The solution is a serious fire hazard. Do not smoke or go near naked flames during or shortly after use.
Disposal Do not throw away any unused medicine via wastewater or household waste; ask your pharmacist for proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Betadermic found in:

A-Z Index: